EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report

Hisham AlSharif, Veronika Danchine, Kira Deekollu, Merve Hasanov, Richard Wu, Tarek Haykal, Antonio Faieta, Claire F Verschraegen iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Hisham AlSharif und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, United Stat…. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Programmed Cell Death 1 Receptor, Skin Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC), who failed cemiplimab, have a poor prognosis, with most patients dying of disease. Second-line therapies consist of additional immunotherapy, epidermal growth factor receptor (EGFR) inhibitors, chemotherapy, salvage surgery, or radiotherapy. Outcomes in this setting remain poorly characterized. We review the first 2 options for our population. The study objective was to describe non-clinical-trial/off-label immunotherapy treatments for advanced, recurrent, or refractory cSCC. Patients This single-institution retrospective case series took place at The Ohio State University Comprehensive Cancer Center, a high-volume academic medical oncology practice.

Methods

We reviewed the electronic medical records of patients who underwent systemic treatments for advanced cSCC. Patient demographics, clinicopathologic history, cancer data, treatments, and outcomes were abstracted. Overall response and progression-free survival by clinical judgment and overall survival rates were described.

Results

A total of 21 patients were included. Thirteen received cetuximab and 12 ipilimumab after failure of surgery and/or radiation, and of a programmed cell death protein 1 (PD-1) monoclonal inhibitor (primarily cemiplimab). Four patients are included in both cohorts. Durable complete responses were observed only in patients treated with ipilimumab. Otherwise, all other surviving patients had salvage surgery after some response to second line therapy.

Conclusions

In this salvage setting, ipilimumab demonstrated a 33% response rate, including complete responses with durable survival. Cetuximab induced response in patients pretreated with cemiplimab whether they had responded or not to this immunotherapy. Most cetuximab-treated patients died within 1-2 years, unless salvaged with surgery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cutaneous Squamous Cell CarcinomaProgrammed Cell Death 1 ReceptorSkin NeoplasmsCarcinoma, Squamous CellHumansFemaleMaleAgedRetrospective StudiesMiddle AgedAged, 80 and overAntibodies, Monoclonal, HumanizedCetuximabSalvage TherapyDrug Resistance, NeoplasmIpilimumab

Stichwörter der Autor:innen

biological therapycancer outcomescutaneous squamous cell carcinomatreatment immunotherapy

Substanzen

Programmed Cell Death 1 ReceptorPDCD1 protein, humanAntibodies, Monoclonal, HumanizedCetuximabcemiplimabIpilimumab

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, United States.

ORCID-Profile: Claire F Verschraegen

Förderung

  • NCI NIH HHS
  • NCI

Zitieren

APA

AlSharif, H., Danchine, V., Deekollu, K., Hasanov, M., Wu, R., Haykal, T., Faieta, A., & Verschraegen, C. F. (2026). Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report. The Oncologist. https://doi.org/10.1093/oncolo/oyag038

Vancouver

AlSharif H, Danchine V, Deekollu K, Hasanov M, Wu R, Haykal T, et al. Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report. The Oncologist. 2026. doi:10.1093/oncolo/oyag038

BibTeX
@article{AlSharif2026,
  author = {AlSharif, Hisham and Danchine, Veronika and Deekollu, Kira and Hasanov, Merve and Wu, Richard and Haykal, Tarek and Faieta, Antonio and Verschraegen, Claire F},
  title = {Second-line treatments for patients with programmed cell death protein 1-refractory cutaneous squamous cell carcinomas: a brief report},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag038}
}
Kostenlos starten →